Key Announcements: 1. Changan Automobile announced plans to repurchase its A-shares with a value between 700 million yuan and 1.4 billion yuan. The total company share repurchase program is valued at 1-2 billion yuan, which includes a B-share repurchase of 300-600 million yuan. The purpose of the repurchase is to reduce the company's registered capital. The maximum price for repurchasing A-shares is set at 17.16 yuan per share, and for B-shares, it is 6.17 Hong Kong dollars per share.
2. Seres Group reported its February 2026 new energy vehicle sales were 12,760 units, a decrease of 28.48% year-on-year. Production for new energy vehicles in February was 11,028 units, down 35.06% compared to the same period last year. Sales of Seres-branded vehicles specifically were 10,003 units, a 33.34% decline.
3. Yongtai Technology announced the cancellation of its Shaowu Yongtai project for an annual production of 200,000 tons of electrolyte. Concurrently, the company signed a new agreement for a 200,000-ton lithium battery electrolyte project in Jiangsu Binhai Economic Development Zone, with an estimated total investment of 500 million yuan.
Trading Halts & Risk Disclosures: 1. TKD Crystal Technology, which saw its stock price rise by the daily limit for two consecutive sessions, stated that its quartz crystal resonators and oscillators can be applied in humanoid robots and optical modules, but related business is currently still in the market promotion phase.
2. YS Group, also up by the daily limit for two sessions, clarified that it is not currently engaged in any mining-related business.
3. China Rare Earth Nonferrous Metals Co.,Ltd., whose stock price also increased by the daily limit for two consecutive trading days, disclosed that as of the announcement date, there is no material information that should be disclosed but has not been.
4. Hengtong Optic-Electric commented that the global optical fiber and cable market environment is normal, but the impact of price fluctuations for some products on future performance requires comprehensive judgment.
5. China Tianying, another stock with two consecutive limit-up sessions, noted that its new growth driver, hydrogen-based energy products, is still in the investment phase and has not yet generated revenue.
Earnings Reports: 1. Zzgood reported a net loss of 45.8397 million yuan for 2025. 2. Shenghui Integration announced a 2025 net profit of 154 million yuan, a year-on-year increase of 34.91%. 3. Weixing Shares posted a 2025 net profit of 642 million yuan, a decrease of 8.38% compared to the previous year. 4. Xinbao Co., Ltd. reported a 2025 net profit of 1.002 billion yuan, down 4.85% year-on-year.
Share Repurchases & Changes in Holdings: 1. A shareholder holding more than 5% of Zhongjuxian plans to increase their holdings by 50-100 million yuan. 2. New Industry plans to repurchase 50-100 million yuan worth of shares for employee stock ownership or equity incentive plans. 3. Shareholder Zhicheng Guangyi intends to reduce its stake in Haohandeep by no more than 3%. 4. Controlling shareholder Li Weiguo plans to reduce his stake in Geoenvironment by up to 3%. 5. Shareholder Wang Quangen intends to reduce his stake in Shenghe Resources by no more than 1%. 6. Controlling shareholder Yongding Group plans to reduce its stake in Yongding Co., Ltd. by no more than 1%. 7. Controlling shareholder Xu Jiuzhen plans to reduce his stake in Aladdin by no more than 0.902%.
Major Contract Awards: 1. JCHX Mining Management signed a 211 million yuan routine operating contract. 2. Tongda Cable & Wire pre-won a 151 million yuan project from China Southern Power Grid. 3. Far East Co., Ltd.'s subsidiary won project orders totaling 887 million yuan. 4. Kangzhi Pharmaceutical's wholly-owned subsidiary was selected for the renewal procurement of drugs whose national centralized procurement agreements have expired. 5. Fangsheng Pharmaceutical's products were selected for the renewal procurement of drugs whose centralized procurement agreements have expired. 6. Jinshi Yazhou's subsidiary, Asia Pharmaceutical, had its domperidone tablets selected for the renewal procurement of drugs whose national centralized procurement agreements have expired.
Comments